NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...

Missouri woman with autism has a request for the Chiefs: she wants to be the team’s water girl Ye shocked at the Grammys red ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Allstate HBCU Legacy BowlSC State's Chennis Berry to co-head coach TEAM GAITHER at the legacy bowl featuring MEAC and CIAA ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades.